Brought to you by 
Alnylam, Arrowhead swap IP
11 Oct 2016
Executive Summary
RNAi therapeutics developer Alnylam Pharmaceuticals Inc. has licensed nanomedicine firm Arrowhead Research Corp. rights to IP for use in the discovery, development, and commercialization of an RNAi therapeutic aimed at hepatitis B (HBV). At the same time, Arrowhead has licensed Alnylam rights to its Dynamic PolyConjugate (DPC) technology for use in developing an RNAi therapy for an undisclosed target in the Alnylam 5x15 program.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alnylam, Arrowhead swap IP
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice